Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026
Autonomix Medical, Inc. announced that two abstracts showcasing their transvascular nerve-targeting technology have been accepted for presentation at EuroPCR 2026. This recognition highlights clinical interest in their approach to neuropathic pain mitigation, particularly for pancreatic cancer. The company aims to advance awareness of their innovative technologies at international forums.
THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking place May 19–22, 2026 in Paris, France.